In 2008, the International Diabetes Federation (IDF) Taskforce on Epidemiology and Prevention released a consensus statement recommending targeted screening for obstructive sleep apnoea (OSA) in people with obesity and type 2 diabetes with classic OSA symptoms, and screening for diabetes, hypertension and dyslipidaemia in those with OSA. We conducted a survey to gain a greater understanding of current practice in relation to the IDF recommendations for the assessment of patients in diabetes clinics in the UK. An online survey that was made accessible to diabetes healthcare professionals with the support of the websites of several diabetes organisations was performed. Most (approximately two-thirds) of diabetes healthcare professionals who responded to this survey were not aware of the IDF recommendations either for diabetes screening in OSA patients or for OSA assessment in type 2 diabetes and obesity. Participants indicated that their local diabetes guidelines did not incorporate assessment for OSA in those deemed to be at risk. Furthermore, most participants perceived OSA investigations to be primarily the domain of the respiratory team rather than the diabetes team. The observations from this survey provide a better understanding of the application and impact of the IDF guidance in diabetes clinics. Br J Diabetes Vasc Dis 2014;14:105-108 
Introduction
Changes in sleep breathing patterns termed SDB are associated with obesity and/or type 2 diabetes. SDB is characterised by a spectrum of altered sleep homeostasis that ranges from simple snoring to OSA with excessive daytime sleepiness. In OSA, repeated apnoeas or hypopnoeas occur during sleep. An apnoea is defined as the complete cessation of airflow for at least 10 seconds. A hypopnoea is defined as a reduction in airflow that is followed by an arousal from sleep or a decrease in oxyhaemoglobin saturation. 1 Formal polysomnography counts the number of apnoeas and hypopnoeas per hour during sleep and the AHI (frequency of apnoea and/or hypopnoea) is used to diagnose and classify the severity of OSA 2 ( Table 1 ). The frequency of oxygen desaturation episodes and severity of somnolence symptoms are also used. 4 The estimated prevalence of moderate to severe OSA is 13% in men and 6% in women between 30 and 70 years. 5 The major risk factors for OSA are obesity, gender and increasing age, 6 and OSA is associated with a clustering of clinical cardio-metabolic manifestations including hypertension and type 2 diabetes. In OSA recurrent episodes of upper airway obstruction and changes in intra-thoracic pressure result in recurrent periodic oxygen desaturations, with frequent sleep arousals and fragmented sleep. 7, 8 It has been estimated that up to 40% of OSA patients will have diabetes, 9 and in patients with diabetes the prevalence of OSA may be up to 23%. 10 Prevalence estimates of OSA in severe obesity have been reported to be 40-90%. 11 Patients may be unaware of the association between OSA and type 2 diabetes. The symptoms and signs of OSA may not be perceived relevant to their 12 Despite the absence of RCT data supporting cardiovascular risk reduction with CPAP treatment, we know that cardiovascular disease risk is increased in OSA. 13 There is also evidence that OSA may be associated with microvascular complications such as diabetic retinopathy, 14 nephropathy 15 and neuropathy. 16 In 2008, the IDF Taskforce on Epidemiology and Prevention released a consensus statement that recommended a targeted approach to screen individuals with type 2 diabetes and obesity for SDB. 17, 18 Briefly, the IDF recommended that healthcare professionals should consider the possibility of OSA in patients with type 2 diabetes and work in tandem with the local sleep service to provide a clinically appropriate process of assessment, referral and intervention. 18 The purpose of this survey was to gain a greater understanding of current practice in relation to the IDF recommendations for assessment of OSA in patients attending diabetes clinics.
Methods
An online survey open to all health professionals caring for patients with diabetes in the UK was conducted for four months (December 2013 to March 2014). Data were collected using a questionnaire consisting of seven questions designed in light of the IDF statement ( Table 2 ). The survey was publicly announced on the ABCD and Diabetes UK websites and in the Diabetes UK professional newsletter (Update, December 2013), and on the YDEF website which provided the links to access the online survey. In order to maintain confidentiality all responses were anonymous.
The first two sections of the questionnaire sought to determine demographic data (location of provision of diabetes care and role of the respondent). Questions 1 and 2 aimed to gauge current awareness of the IDF guidance; question 3 to investigate adoption of the IDF recommendations by local diabetes pathways; questions 4 and 5 ascertained the perceived roles for investigating OSA in diabetes patients.
Results
A total of 62 responses were received, mainly from hospitalbased physicians (Figure 1) , and showed that a minority of respondents were aware of the IDF guidelines and their implications for practice, but 78% of respondents noted that diabetes patients with suspected OSA are investigated by the respiratory team (Table 3) . Appendix 1 (available online at www.bjdvd.com) documents questionnaire responses according to role and location. It is noteworthy that all respondents did not answer all questions.
Discussion
The majority (approximately two-thirds) of diabetes healthcare professionals who responded to this survey were not aware of the IDF recommendations either for diabetes screening in OSA patients or for OSA assessment in type 2 diabetes and obesity. Secondly, most participants indicated that their local diabetes guidelines did not incorporate assessment for OSA in those deemed to be at risk. Thirdly, for the vast majority of participants, assessments were deemed to be primarily the domain of the respiratory team and not the diabetes team.
A beneficial effect of OSA treatment with CPAP in terms of blood pressure reduction was found in patients with type 2 diabetes, 19 although the research on the of influence of CPAP therapy on glucose homeostasis has yielded mixed findings. 20 Nevertheless, it has been proposed that there may be a role for a multifaceted approach for these individuals in order to manage their cardio-metabolic risks. 21 A recent observational study of OSA patients with type 2 diabetes assessed clinical outcomes and costeffectiveness of CPAP treatment compared with non-treatment. It was found that CPAP use was associated with significantly lower blood pressure, improved glycaemic control, and was more costeffective than no treatment with CPAP, 22 and a strategy has been proposed to identify, screen and diagnose patients with type 2 diabetes and OSA. 23 The Epworth Sleepiness scale is a validated questionnaire to assess the severity of sleepiness symptoms and is a simple screening tool that could be used for patients suspected of SDB. However, it should be borne in mind that although hypersomnolence symptoms may relate to micro-arousals and to changes in sleep architecture, it is non-specific and not always associated with OSA. Therefore it is not sufficiently discriminating to diagnose OSA. 24 Depending on services available, a referral for sleep studies or to the relevant sleep team for further assessment may be necessary. Lifestyle recommendations such as weight reduction for overweight or obese patients, smoking cessation, avoidance of sedatives, decreasing alcohol consumption and proper sleep hygiene may be recommended.
The treatment of OSA aims to reduce daytime sleepiness. CPAP is recommended as a treatment option for individuals with moderate or severe symptomatic OSA given the effects on blood pressure, implications for quality of life and driving safety. 25 There is evidence that non-sleepy OSA patients treated with CPAP have not shown effective decreases in blood pressure and it is possible that non-sleepy asymptomatic OSA patients may face a different level of risk from those who are sleepy. 26 This study has several limitations. Despite public announcements of the survey and engaging the help of organisations including the ABCD, the YDEF and Diabetes UK, which has an estimated 6,000 professional members (Richard Elliot, Personal Communication, 17 June 2014), there were only 62 respondents, so there is likely to be a significant non-response bias given the limited sample size. A higher response rate using a validated questionnaire would increase confidence in the generalisability of the findings.
Nevertheless awareness of OSA and taking it into consideration as part of our holistic patient assessment are very important. Other Allied Healthcare Professional 11% (7) Key messages
• OSA is a common co-morbidity in diabetes and obesity • A history of snoring, excessive daytime somnolence and witnessed apnoeic events may be suggestive of OSA • A pro-active approach is encouraged to identify patients at risk of OSA
